Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | Chief Medical Officer | April 16, 2026 | April 17, 2026 |
| TScan Therapeutics, Inc.TCRX · Entity 7255 | Director | May 20, 2026 | May 22, 2026 |
| Xencor IncXNCR · Entity 4487 | Director | June 16, 2026 | July 08, 2026 |
| eFFECTOR Therapeutics, Inc.EFTR · Entity 89916 | Director | June 13, 2024 | June 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date April 16, 2026 · Filed April 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2036-04-15 | Direct | 100,000 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 100,000 · Balance 100,000 F1: One-fourth of the shares subject to the option vest on February 25, 2027 and 1/48th vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth of the shares subject to the option vest on February 25, 2027 and 1/48th vest monthly thereafter.
TScan Therapeutics, Inc.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2036-05-20 | Direct | 67,000 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 67,000 · Balance 67,000 F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.
Xencor Inc
Report date June 16, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,974 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 10,302 · Balance 29,974 F1: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.20 · Expires 2036-06-15 | Direct | 20,604 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Grant · Acquired 20,604 · Balance 20,604 F2: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant.
F2: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027.
eFFECTOR Therapeutics, Inc.
Report date June 13, 2024 · Filed June 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.38 · Expires 2034-06-12 | Direct | 800 |
Reported balance
After 2024-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-13 · Grant · Acquired 800 · Balance 800 F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest in full on the earlier to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest in full on the earlier to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sierra Oncology, Inc.
Report date July 01, 2022 · Filed July 01, 2022
Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 1
1 source rowRow 1 · 2022-07-01 · Disposition to issuer · Disposed 10,000 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 0 |
Reported balance
After 2022-07-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2022-07-01 · Disposition to issuer · Disposed 5,000 · Balance 0 |
| Stock Option (right to buySEC Table II · derivative / convertible security · Conversion / exercise price $268.20 · Expires 2025-06-10 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-01 · Disposition to issuer · Disposed 11,744 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F1: The option fully vested on June 11, 2019. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $263.20 · Expires 2016-03-08 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-07-01 · Disposition to issuer · Disposed 2,061 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F3: The option fully vested on January 1, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.80 · Expires 2026-09-30 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-07-01 · Disposition to issuer · Disposed 11,399 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F4: The option fully vested on September 30, 2019. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.00 · Expires 2027-03-06 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-07-01 · Disposition to issuer · Disposed 1,749 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F5: The option fully vested on January 1, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.40 · Expires 2028-03-06 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-07-01 · Disposition to issuer · Disposed 4,508 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F6: The option fully vested on January 1, 2022. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.40 · Expires 2029-03-04 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-07-01 · Disposition to issuer · Disposed 4,999 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F7: The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.31 · Expires 2030-02-25 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-07-01 · Disposition to issuer · Disposed 167,091 · Balance 0 F9: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F8: The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.15 · Expires 2030-08-12 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-07-01 · Disposition to issuer · Disposed 49,000 · Balance 0 F9: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F10: On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.73 · Expires 2031-03-15 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-07-01 · Disposition to issuer · Disposed 30,000 · Balance 0 F9: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F11: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.54 · Expires 2032-03-14 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-07-01 · Disposition to issuer · Disposed 50,000 · Balance 0 F9: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F12: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option fully vested on June 11, 2019.
F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger.
F3: The option fully vested on January 1, 2020.
F4: The option fully vested on September 30, 2019.
F5: The option fully vested on January 1, 2021.
F6: The option fully vested on January 1, 2022.
F7: The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.
F8: The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F9: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
F10: On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
F11: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
F12: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2017 Filed Mar 8, 2017 17:45 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001209191-17-019364 · doc4.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2027-03-06 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on January 1, 2018, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 17:09 UTC | Sierra Oncology, Inc. DNAI · Entity 125698 | GrantStock Option (right to buy) · Derivative | 456,000 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001209191-16-144433 · doc4.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,000 Underlying: Common Stock · 456,000 shares Expires 2026-09-30 F1 · derivative.exercise_date: The option vests as to 2.7778% of the total shares monthly, beginning on October 30, 2016, with 100% of the total shares vested and exercisable on September 30, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.